News | July 08, 2009

Palliative RT Prolongs Survival in Patients with EHC

July 8, 2009 - RT prolongs survival in patients with extrahepatic cholangiocarcinomas (EHC) are rare tumors of the biliary tree, according to a study published in International Journal of Radiation Oncology - Biology - Physics.*

The researchers set out to examine the role of adjuvant and palliative RT in the treatment of EHC in a large patient population, by doing a retrospective analysis of 4,758 patients with EHC collected from the Surveillance, Epidemiology and End Results database. The primary endpoint was overall survival.

Twenty-eight percent of the patients underwent surgery, 10 percent radiation therapy (RT), 14.7 percent underwent both surgery and RT, and 46.4 percent had neither RT or surgery. The median age of the patient population was 73 years (range, 23–104), 52.5 percent were men, and 80.7 percent were white. The median overall survival time was 16 months, 9 months, and 4 months for surgery and RT, surgery, RT, and no RT or surgery, respectively. The overall survival was significantly different between the surgery and surgery and RT groups (p

These results suggest that palliative RT prolongs survival in patients with EHC. The benefit associated with surgery and RT was significant on univariate analysis but not after controlling for potential confounders using the propensity score. Future studies should evaluate the addition of chemotherapy and biologic agents for the treatment of EHC.

*Int J Radiat Oncol Biol Phys. 2009 Jun 16;74(4):1-5, ET Shinohara, M Guo, JM Metz

For more information:

Related Content

RaySearch Developing RayCommand Treatment Control System for U.K. Proton Therapy Facility
Technology | Radiation Therapy | December 10, 2018
RaySearch has decided to develop a treatment control system, RayCommand, to act as a link between its RayStation...
Mirada Medical Joins U.K. Consortium Exploring Healthcare AI
News | Artificial Intelligence | December 04, 2018
Mirada Medical, a leading global brand in medical imaging software, will form part of an artificial intelligence (AI)...
Ohio State University to Open Region’s First Proton Therapy Facility

Image courtesy of The Ohio State University James Comprehensive Cancer Center

News | Proton Therapy | November 21, 2018
The Ohio State University Wexner Medical Center and the Arthur G. James Cancer Hospital and Richard J. Solove Research...
Immune Inflammatory Levels Linked to Disease-Free Survival in Prostate Cancer
News | Prostate Cancer | November 19, 2018
Data from a validation study of a high-risk prostate cancer trial suggests that higher levels of pretreatment...
Merit Medical Completes Acquisition of Cianna Medical
News | Women's Health | November 14, 2018
Disposable device manufacturer Merit Medical Systems Inc. announced the closing of a definitive merger agreement to...
Videos | ASTRO | November 08, 2018
ITN Editor Dave Fornell took a tour of some of the most innovative technologies on display on the expo floor at the 
The Fujifilm FCT Embrace CT System displayed for the first time at ASTRO 2018.
360 Photos | 360 View Photos | November 07, 2018
Fujifilm's first FDA-cleared compu...
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for radiation therapy displayed for the first time since gaining FDA clearance in 2018. It was displayed at the American Society for Radiotherapy and Oncology (ASTRO) 2018 annual meeting. Read more about this system at ASTRO 2018. #ASTRO18 #ASTRO2018
360 Photos | 360 View Photos | November 07, 2018
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for...